REG - OptiBiotix Health - Notice of AGM

OptiBiotix HealthAnnouncement

17/05/2019 07:05

RNS Number : 3230Z
OptiBiotix Health PLC
17 May 2019
 


OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
Notice of AGM
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the Annual General Meeting will be held on 11 June 2019 at 3pm at Foxhills Country Club, Stonehill Road, Ottershaw, Surrey KT16 0EL.
 
A copy of the notice of AGM will be available on the Company's website today.
 
For further information, please contact:
 



OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Cairn Financial Advisers LLP (NOMAD)


Tel: 020 7213 0880




Liam Murray / Jo Turner








 
finnCap (Broker)


 
Tel: 020 7220 0500




Geoff Nash / Kate Bannatyne (Corporate Finance)








Camille Gochez (Corporate Broking)


















Walbrook PR Ltd


Tel: 020 7933 8780 or optibiotix@walbrookpr.com




Anna Dunphy


Mob: 07876 741 001








 
 
About OptiBiotix - www.optibiotix.com 
 
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 
 
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
 
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 
 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOAAFMATMBTBBML